As required by CVS/caremark, for drug products that potentially qualify under Part B or Part D, a pharmacy provider must promptly obtain any necessary information from the enrollee or prescriber to properly submit the drug for processing (e.g., to the Part B plan or the Part D plan).

A MedImpact plan has activated the emergency service to allow overrides for members displaced by the emergency effective 08/20/2015 through 11/18/2015.

On August 18, 2015, Merck and Sandoz, in conjunction with the U.S. Consumer Product Safety Commission, announced a consumer level recall of multiple lots of brand and generic TEMODAR (temozolomide) capsules, due to potential cracks in the child-resistant bottle caps.

Notice of Product Recall— Specific lots of REFRESH® Lacri-Lube®, REFRESH P.M. ®, FML® (fluorometholone ophthalmic ointment) 0.1%, and BLEPHAMIDE (sulfacetamide sodium/prednisolone acetate ophthalmic ointment) 10%/0.2% by Allergan

MHS is excited to announce that we will soon reimburse Medication Therapy Management (MTM) services for targeted high risk members covered under the Healthy Indiana Plan Plus membership or Hoosier Care Connect program through a joint partnership with our pharmacy benefit manger US Script and our MTM vendor Mirixa.